Compare MTEK & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTEK | MBIO |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Israel | United States |
| Employees | 16 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.1M |
| IPO Year | 2021 | 2023 |
| Metric | MTEK | MBIO |
|---|---|---|
| Price | $0.42 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 511.9K | 36.3K |
| Earning Date | 09-02-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $405.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.37 |
| 52 Week High | $2.82 | $1.52 |
| Indicator | MTEK | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 26.16 | 29.78 |
| Support Level | N/A | N/A |
| Resistance Level | $1.12 | $0.56 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 14.87 | 10.84 |
Maris Tech Ltd is a B2B provider of intelligent video transmission technology with AI acceleration for edge platforms, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures, and commercially sells miniature intelligent video and audio surveillance and communication systems with AI acceleration for the professional, civilian, and home security markets. Its products and solutions are sold as off-the-shelf, standalone, and ready-to-use products, or as customized components that meet customers' requirements and integrate into their systems and products. Its customers include companies operating in the drone, robotic, defense, HLS, intelligence gathering, autonomous vehicle, and space markets. It generates maximum revenue from Israel.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.